Syncona commits £63.5m to Resolution Therapies - Vox Markets

Syncona Commits £63.5m To Resolution Therapies - Vox Markets

6 days from now

Oct 3, 2024  · Syncona Limited NPV Follow | SYNC announced on Thursday that it has committed £63.5m in series B financing to Resolution Therapeutics, a portfolio company focused on …

voxmarkets.co.uk

Syncona Commits £63.5m To Resolution Therapies - Share …

6 days from now

Syncona commits £63.5m to Resolution Therapies. 3rd Oct 2024 12:14 ... It said the first tranche of £22m had already been invested, bringing Syncona's holding value in Resolution to £63.6m, …

sharecompare.co.uk

Syncona Commits £63.5m To Resolution Therapies - Sharecast.com

6 days from now

Oct 3, 2024  · Syncona announced on Thursday that it has committed £63.5m in series B financing to Resolution Therapeutics, a portfolio company focused on macrophage therapy for …

sharecast.com

Resolution Therapeutics Raises £63.5 Million In Series B Financing …

6 days from now

Oct 3, 2024  · Syncona Ltd, (“Syncona” or the “Company”), a leading life science investor focused on creating, building and scaling a portfolio of global leaders in life science, today announces …

pharmiweb.com

Syncona Ploughs £63.5m Into Resolution Therapeutics

6 days from now

Oct 3, 2024  · Syncona has committed £63.5m in a Series B financing of Resolution Therapeutics, a company focused on unlocking the regenerative potential of macrophage therapy for the …

theaic.co.uk

Syncona Commits £63.5m To Resolution Therapies - London South …

6 days from now

Oct 3, 2024  · Syncona commits £63.5m to Resolution Therapies | Financial News

lse.co.uk

Resolution Therapeutics Announces A £26.6m Series A ... - Syncona

6 days from now

May 6, 2024  · Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases characterised by life-threatening …

synconaltd.com

Resolution Therapeutics Announces A £26.6m Series A Financing …

6 days from now

London, 2 December 2020 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases characterised by life …

resolution-tx.com

Resolution Therapeutics Announces A £10m Extended Series A

6 days from now

Apr 5, 2022  · Broadening research pipeline into allogeneic macrophages for the treatment of liver disease - London, 5 April, 2022 – Resolution Therapeutics Limited (“Resolution”), a …

synconaltd.com

Resolution Therapeutics | Pre-clinical Companies | Portfolio

6 days from now

Market opportunity ­1-2 million people estimated to be affected by liver cirrhosis across major Western markets 1. The global liver transplantation market in 2023 was $1.5 billion in 2023 2. …

synconaltd.com